Arteriovenous Fistula Market

SKU: DMPH3137 | Last Updated On: Oct 25 2022 | Available Formats

>Arteriovenous Fistula Market Expected to reach a high CAGR of 5.9% By 2029: DataM Intelligence

Global Arteriovenous Fistula Market is segmented By Type (Radial Cephalic fistula, Brachial Cephalic, Brachial Basilic Transposition), By Treatment Methods (Endovascular embolization, Microsurgery, Stereotactic radiosurgery), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


[170 Pages Report] Arteriovenous Fistula Market was valued at USD YY million in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 5.9% during the forecast period (2022-2029).

Arteriovenous Fistula Market - Strategic Insights



Market CAGR


Segments Covered

By Type, By Treatment Methods, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here

The interruption of blood supply caused by an irregular link between a vein and an artery is known as an arteriovenous fistula. Blood passes straight from lungs to veins in the event of an arteriovenous fistula, bypassing capillaries. Capillary tissues thus obtain smaller supplies of oxygen (blood supply) and raise the risk of complications with blood pressure. Fistulas between the arteries and veins may be congenital or inherited. Congenital fistula occurs during embryonic development and mainly affects blood vessels in the lower extremities. While acquired fistula typically happens when veins and arteries are impaired, the healing process results in two parallel vein and artery connections. Further, the arteriovenous fistula is formed on the arms, kidneys, brain, or certain parts of the legs. Penetrating damage, arterial vein breakup, and inflammatory necrosis of adjacent veins all increase the risk of an arteriovenous fistula. With consistent efforts of key players to develop novel therapeutics for the treatment of arteriovenous fistula, the global arteriovenous fistula market is seeing fast growth in the forecast period.

Market Dynamics:

Growing demand for advanced treatment methods

Over the projected period, the arteriovenous fistulas care market is expected to expand as players develop new treatment methods such as photodynamic therapy, antiangiogenic therapy, and other sclerotherapy methods. The successful form of therapy for a complete recovery in a simple way is still in the development process, which inspires players to come up with innovative treatment technologies. Further, growing FDA approvals for noninvasive devices for arteriovenous fistula creation have resulted in the market growth over the forecast period.

Moreover, the optimal access for hemodialysis transmission is known to be an autogenous arteriovenous fistula. On the other hand, the surgical development of an arteriovenous fistula is synonymous with less-than-ideal technical performance, and numerous procedures are often required to aid maturation or preserve early patency. With these deficiencies, many new methods are now under study that can enhance surgical procedures and/or performance. Minimally invasive new system manufacturing methods are being studied, with early research findings available. Furthermore, the presence of a vast number of therapeutics in the research pipeline and optimistic government policies would improve the demand for arteriovenous fistula over the forecast period.

Market players are improving their treatment approaches, such as antiangiogenic therapy, photodynamic therapy and an additional form of sclerotherapy, as factors contributing to this development. Developing an appropriate therapeutic plan for the full treatment of the condition is a challenging process still in progress. It generated the need for new technologies and improvements in the treatment process for industry leaders to come up with. The market's development is hampered by a lack of awareness about the disease.

However, the lack of effective therapeutics that can address the particular cause of arteriovenous fistula, the other hand, would restrict the market's expansion. Often recovery may take longer than expected, or access can fail to mature. Further, to access the AV fistula for dialysis, needles are required.

Market Segmentation:

The radial cephalic fistula segment is projected to be the dominant segment in the market during the forecast period.

Based on the type, the arteriovenous fistula market has been classified into the radial cephalic fistula, brachial cephalic, brachial basilic transposition.

As part of the Kidney disease outcomes quality initiative (KDOQI), the 2006 recommendations suggested by the National Kidney Foundation suggest that a radiocephalic fistula be the first alternative for fistula creation. This is because the radiocephalic fistula has a lower rate of steal syndrome than upper arm fistulas and because developing this forearm fistula retains the possibility of creating a more proximal fistula in the future if this access fails. The maturation rate for radiocephalic fistulas, however, is low, with one analysis finding that up to two-thirds of radiocephalic fistulas have not matured.

 The global arteriovenous fistula market is segmented based on treatment methods, which includes endovascular embolization, microsurgery, stereotactic radiosurgery.

The endovascular embolization segment is expected to account for a significant market share in the Arteriovenous Fistula market. Endovascular embolization is a recent therapeutic procedure for arteriovenous malformations (AVM). During this procedure, a catheter is implanted through the groin into the arteries in the brain that contribute to the AVM, and material is injected into the arteries. This injection blocks the artery, limiting blood flow into the AVM. Usually, endovascular embolization alone does not remove the AVM and is, thus, almost exclusively used as a preliminary step in either microsurgical resection or stereotactic radiotherapy preparation.

Geographical Penetration:

North America region is expected to dominate the global Arteriovenous Fistula market

Based on geography, the study analyzes the arteriovenous fistula market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Geographically, owing to positive measures by the U.S. government to create new therapeutics for arteriovenous fistula disease, North America leads the worldwide arteriovenous fistula market. Europe is the second-largest market for arteriovenous fistulas after the U.S. The growth of this market in Europe is mainly due to the growing occurrence of arteriovenous fistula in this region, combined with a strong demand for arteriovenous fistula therapy.

Moreover, owing to the growing healthcare understanding among the patient population, Asia-Pacific countries are the developing countries in the worldwide arteriovenous fistula industry.

Competitive Landscape:

The arteriovenous fistula market is moderately competitive, owing to the presence of major market players in key regions such as the US, China, India and others. The key arteriovenous fistula players which are contributing to the growth of the global market include Pervasis Therapeutics, Inc., Proteon Therapeutics, Inc., Medtronic, Cook Medical, Fresenius Medical Care AG & Co. KGaA, Poly Medicure Limited, Becton Dickinson and Company, Braun Melsungen Ag, Teleflex Incorporated among others. The major players are adopting new product launches and expansion strategies for global growth in the arteriovenous fistula market. In September 2020, Medtronic, the global leader in medical technology, acquired Avenue Medical, a privately held medical device company. Avenu's Percutaneous Fistula Creation Technology strengthens the Medtronic Peripheral Vascular Access Portfolio and Reinforces Medtronic's Commitment to Improving Outcomes for Patients with End-Stage Renal Disease. In September 2020, Medtronic expanded its dialysis access position with Avenu Medical buyout. The company plans to acquire Avenu Medical, which produces a system for minimally invasive creation of arteriovenous (AV) fistulae for end-stage renal disease patients who need to establish dialysis access. In January 2020, Cook Medical and Bentley announced their collaboration strategy for a clinical trial involving Cook's fenestrated and branch stent grafts and Bentley's covered stents.

COVID-19 Impact:

Negative impact on the global arteriovenous fistula market.

The global healthcare system has been challenged by a recent epidemic known as coronavirus disease 2020 (COVID-19). More than 1,000,000 positive cases had been registered by the beginning of April, with 51,737 deaths. A global solution to sustain the healthcare infrastructure is crucial during a pandemic. The primary justification for delaying elective treatments is ensuring the healthcare system can keep up with the pandemic. There have been various questions about whether to postpone vascular operations and the safety steps needed to care for a patient with COVID-19. Moreover, hemodialysis vascular accesses are considered the patient's lifeline, and their upkeep is vital for care consistency. The Brazilian Society of Nephrology developed these recommendations for healthcare facilities, elaborating on the value of conducting procedures for the planning and protection of vascular accesses, following the lead of organizations in other countries affected by the COVID-19 pandemic. Non-elective treatments, as well as the transition from the use of non-tunnel catheters to tunnel catheters causing less morbidity, are the development of conclusive accesses for hemodialysis, grafts and arteriovenous fistulas.

The global arteriovenous fistula market report would provide an access to approximately 53 market data tables, 40 figures and 170 pages


What is the Arteriovenous Fistula Market growth?

The market is growing at a CAGR of 5.9%.

What is Arteriovenous Fistula Market size in 2021

The Arteriovenous Fistula Market size was valued at USD YY million in 2021.

Who are the key players in Arteriovenous Fistula Market?

Proteon Therapeutics, Inc., Medtronic, Cook Medical, Fresenius Medical Care AG & Co. KGaA, Poly Medicure Limited, Becton Dickinson and Company.

Trending Topics

Dental Biomaterials Market

Anticoccidial Drugs Market

Healthcare Analytics Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!